Short Interest in Definitive Healthcare Corp. (NASDAQ:DH) Grows By 23.3%

Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 3,710,000 shares, an increase of 23.3% from the March 15th total of 3,010,000 shares. Approximately 9.1% of the company's shares are short sold. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is currently 3.4 days.

Definitive Healthcare Price Performance

NASDAQ DH remained flat at $2.71 during trading hours on Friday. The company's stock had a trading volume of 347,864 shares, compared to its average volume of 851,717. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. The firm has a market capitalization of $305.99 million, a price-to-earnings ratio of -0.87, a price-to-earnings-growth ratio of 4.06 and a beta of 1.48. The company's 50-day simple moving average is $3.02 and its 200 day simple moving average is $3.98. Definitive Healthcare has a 12 month low of $2.15 and a 12 month high of $7.47.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.04). Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. The firm had revenue of $62.29 million for the quarter, compared to analysts' expectations of $60.60 million. On average, equities research analysts predict that Definitive Healthcare will post 0.16 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Needham & Company LLC restated a "hold" rating on shares of Definitive Healthcare in a report on Thursday, January 16th. Barclays decreased their price target on Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating on the stock in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group dropped their price objective on Definitive Healthcare from $4.50 to $3.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Definitive Healthcare currently has an average rating of "Hold" and an average price target of $5.35.

Hedge Funds Weigh In On Definitive Healthcare

Several large investors have recently bought and sold shares of DH. Nisa Investment Advisors LLC lifted its holdings in Definitive Healthcare by 3,652.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,980 shares of the company's stock worth $29,000 after buying an additional 6,794 shares during the last quarter. Bayesian Capital Management LP purchased a new stake in Definitive Healthcare during the fourth quarter worth approximately $41,000. Ieq Capital LLC acquired a new position in Definitive Healthcare in the fourth quarter valued at approximately $51,000. KLP Kapitalforvaltning AS acquired a new position in Definitive Healthcare in the fourth quarter valued at approximately $54,000. Finally, Two Sigma Securities LLC purchased a new position in Definitive Healthcare in the fourth quarter valued at approximately $56,000. Hedge funds and other institutional investors own 98.67% of the company's stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.